IPI Legacy Liquidation Co Past Earnings Performance
Past criteria checks 0/6
IPI Legacy Liquidation Co's earnings have been declining at an average annual rate of -23.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 118.6% per year.
Key information
-23.8%
Earnings growth rate
116.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 118.6% |
| Return on equity | n/a |
| Net Margin | -353.9% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Investors Still Aren't Entirely Convinced By Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Revenues Despite 50% Price Jump
Apr 17
The Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 30Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%
Mar 26Impel NeuroPharma GAAP EPS of -$1.09 misses by $0.04, revenue of $2.8M misses by $1.04M
Aug 15Impel stock rises as dosing begins in mid-stage trial of INP105 for agitation in autistic people
Jul 19Impel Pharmaceuticals: Under The Radar Despite Upside Potential
Jun 28Impel NeuroPharma reports Q1 results
Jun 07Revenue & Expenses BreakdownBeta
How IPI Legacy Liquidation Co makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 21 | -74 | 77 | 4 |
| 30 Jun 23 | 19 | -92 | 81 | 7 |
| 31 Mar 23 | 15 | -109 | 80 | 11 |
| 31 Dec 22 | 13 | -106 | 78 | 11 |
| 30 Sep 22 | 8 | -108 | 77 | 15 |
| 30 Jun 22 | 5 | -102 | 74 | 18 |
| 31 Mar 22 | 2 | -92 | 65 | 20 |
| 31 Dec 21 | 1 | -77 | 51 | 21 |
| 30 Sep 21 | 0 | -66 | 36 | 25 |
| 30 Jun 21 | 0 | -50 | 22 | 25 |
| 31 Mar 21 | 0 | -48 | 19 | 26 |
| 31 Dec 20 | 0 | -46 | 17 | 28 |
Quality Earnings: IMPL.Q is currently unprofitable.
Growing Profit Margin: IMPL.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMPL.Q is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.
Accelerating Growth: Unable to compare IMPL.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMPL.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: IMPL.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.